Key facts
- Notable investors include Huatai Zijin Investment, Leading Capital Company, Shanghai Lingang Economic Development, DFJ DragonFund China, Shanghai Trust — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Anda Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Anda Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Anda Biopharma
Developer of personalized treatment focusing on tumor neoantigens. The company's treatment is based on AI technology analysis platform, integrating single-cell sequencing, organoid chips and digital twin technology, providing patients with personalized vaccine for cancer and tumor.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Website
- anda-biopharm.com/
- Ownership
- Privately Held (backing)
Anda Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Anda Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Anda Biopharma in its N-PORT filings yet. We sweep new filings monthly.